telephone:+7 (8352) 222-490
Mail:info@interactive-plus.ru
rus eng


  1. Main
  2. Journal "Interactive science"
  3. No 3 (58)
  4. Depressive Spectrum Disorders in Neurological Prac...
Центр научного сотрудничества "Интерактив плюс"
info@interactive-plus.ru
+7 (8352) 222-490
2130122532
Центр научного сотрудничества «Интерактив плюс»
RU
428000
Чувашская Республика
г.Чебоксары
ул.Гражданская, д.75
428000, Россия, Чувашская Республика, г. Чебоксары, улица Гражданская, дом 75
+7 (8352) 222-490
RU
428000
Чувашская Республика
г.Чебоксары
ул.Гражданская, д.75
56.125001
47.208966

Depressive Spectrum Disorders in Neurological Practice: Is There a Place Under the Sun, or Who Should Treat Patients?

Research Article
DOI: 10.21661/r-553461
Open Access
Monthly international scientific journal «Interactive science»
Creative commons logo
Published in:
Monthly international scientific journal «Interactive science»
Authors:
Antsyborov A.V. 1 , Dubatova I. V. 2
Work direction:
Cover aticle
Rating:
Article accesses:
1594
Published in:
eLibrary.ru
1 Mental Health Clinic «Psyche»
2 FSFEI of HE “Rostov State Medical University” of Russian Ministry of Health
For citation:
Antsyborov A. V., & Dubatova I. V. (2021). Depressive Spectrum Disorders in Neurological Practice: Is There a Place Under the Sun, or Who Should Treat Patients?. Interactive science, 9-30. https://doi.org/10.21661/r-553461
  • Metadata
  • Full text
  • Metrics
  • Related articles
UDC 61

Abstract

In the cases of majority of neurological diseases the symptoms of depression have significant influence on the worsening of the quality of patient’s life, regardless of the severity of the neurological disorders. In the most of neurodegenerative diseases the symptoms of depression often precede the appearance of neurological symptoms. Within recent years, numerous studies have been published demonstrating that disorders of depressive spectrum can be considered as a predictor of some types of dementia. Existing data regarding the methods of therapeutic intervention for depression in the clinical practice are rather scarce, scattered and often based on the «personal experience» of neurologists and psychiatrists. In some patients the diagnostics of depression in the context of neurological disorders can be difficult due to the difficulties in the establishing the contact with the patient as well as cognitive deviations related to neurological disorders. In order to facilitate this task, the effective screening diagnostic methods have been developed for the diagnosis of depression in the context of neurological diseases. The results of clinical studies performed within recent years confirm the important role of the neurologist for the evaluation and the treatment of the symptoms of depression, both at the initial stage and at the stage of remission. The purpose of the current review is to systematize the accumulated data on the disorders of depressive spectrum in the context of neurological practice, as well as to demonstrate the role of neurologist in the process of diagnosis and treatment of the symptoms of depression in neurological diseases.

Acknowledgments

Финансирование исследования осуществлялось фармацевтической компании Adamed.

References

  1. 1. Klineova, S. (2020). et al. Psychological resilience is linked to motor strength and gait endurance in early multiple sclerosis. Multiple Sclerosis Journal, Vol. 26, 9.
  2. 2. Lebrun, C. (2020). et al. Efficacy of cognitive behavioral therapy for insomnia comorbid to Parkinson's disease: A focus on psychological and daytime functioning with a single-case design with multiple baselines. Journal of clinical psychology, Vol. 76, 3.
  3. 3. Kumral, E., & Bayam, F. E. (2020). The Role of Neurologist in the Assessment and Treatment of Depression. Turkish Journal of Neurology, Vol. 26.
  4. 4. Nabulsi, L. (2020). et al. Frontolimbic, frontoparietal, and default mode involvement in functional dysconnectivity in psychotic bipolar disorder. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, Vol.. 2. -p. 140-151.
  5. 5. Gunturkun, O., Strockens, F., & Ocklenburg, S. (2020). Brain lateralization: A comparative perspective. Physiological reviews, Vol. 100, 3.
  6. 6. Erlangsen, A. (2020). et al. Association between neurological disorders and death by suicide in Denmark. Jama, Vol. 323, 5.
  7. 7. Chan, Y. L. (2020). E. et al. Treatment-Resistant depression enhances risks of dementia and Alzheimer's disease: A nationwide longitudinal study. Journal of Affective Disorders, Vol. 274, 806.
  8. 8. (1993). World Health Organization et al. The ICD-10 classification of mental and behavioural disorders. Organization.
  9. 9. (2013). American Psychiatric Association et al. Diagnostic and statistical manual of mental disorders (DSM-5(r)). Psychiatric Pub.
  10. 10. Gaebel, W., Zielasek, J., & Reed, G. M. (2017). Mental and behavioural disorders in the ICD-11: concepts, methodologies, and current status. Psychiatria polska.
  11. 11. Carrozzino, D. (2020). et al. The Hamilton Rating Scales for Depression: a critical review of clinimetric properties of different versions. Psychotherapy and psychosomatics, Vol. 89, 3.
  12. 12. Ghaemi, S. N. (2020). Using Psychiatric Rating Scales in Clinical Trials: A Proposal. Journal of Clinical Psychopharmacology, Vol. 40, 5.
  13. 13. Perna, G. (2020). et al. Personalized psychiatry and depression: the role of sociodemographic and clinical variables. Psychiatry investigation, Vol. 17, 3.
  14. 14. Sinanovic, O. (2020). Psychiatric disorders in neurological diseases. Mind and Brain, Springer,. Cham.
  15. 15. Kenangil, G. (2021). et al. Alexithymia, depression, and cognition in patients with Parkinson's disease. Acta Neurologica Belgica, p. 1.
  16. 16. Tran, T. et al. What is normal cognition in depression? Prevalence and functional correlates of normative versus idiographic cognitive impairment. (2021). -. -- . 1. -p. 33. Neuropsychology, Vol. 35, 1.
  17. 17. Altug, H. (2020). et al. Air pollution is associated with depressive symptoms in elderly women with cognitive impairment. Environment international, Vol. 136.
  18. 18. Li, Y. (2020). et al. Brain structural correlates of depressive symptoms in Parkinson's disease patients at different disease stage. Psychiatry Research: Neuroimaging, Vol. 296.
  19. 19. Filipska, K. (2020). et al. Are depression and dementia a common problem for stroke older adults? A review of chosen epidemiological studies. Psychiatric Quarterly, p. 1.
  20. 20. Zeng, Y. Y. (2020). et al. Comparison of poststroke depression between acute ischemic and hemorrhagic stroke patients. International Journal of Geriatric Psychiatry.
  21. 21. Chaturvedi, P. (2020). et al. Depression impedes neuroplasticity and quality of life after stroke. Journal of Family Medicine and Primary Care, Vol. 9, 8.
  22. 22. Maddula, M., & Munshi, S. K. (2020). Readmission to hospital after stroke. Stroke in the Older Person, p. 425.
  23. 23. Alegiani, A. C. (2020). et al. Quality of Stroke Patient Information Applied in Randomized Controlled Trials-Literature Review. Frontiers in neurology, Vol. 11.
  24. 24. Kowalska, K. (2020). et al. Early Depression Independently of Other Neuropsychiatric Conditions, Influences Disability and Mortality after Stroke (Research Study-Part of PROPOLIS Study). Biomedicines, Vol. 8, 11.
  25. 25. Volz, M., Ladwig, S., & Werheid, K. (2021). Gender differences in post-stroke depression: A longitudinal analysis of prevalence, persistence and predictive value of known risk factors. Neuropsychological rehabilitation, Vol. 31, 1.
  26. 26. Fournier, L. E. (2020). et al. Assessment of the progression of poststroke depression in ischemic stroke patients using the patient health questionnaire-9. Journal of Stroke and Cerebrovascular Diseases, Vol. 29, 4.
  27. 27. Li, C. (2020). et al. Association between obstructive sleep apnea and risk of poststroke depression: A hospital-based study in ischemic stroke patients. Journal of Stroke and Cerebrovascular Diseases, Vol. 29, 8.
  28. 28. Khedr, E. M. (2020). et al. Post-stroke depression: frequency, risk factors, and impact on quality of life among 103 stroke patients-hospital-based study. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, Vol. 56, 1.
  29. 29. Sam, S. P. (2020). et al. Post Stroke Depression and Lesion Location: A Hospital based cross sectional study. Kerala Journal of Psychiatry.
  30. 30. Lavados, P. M. et al. Incidence, risk factors, prognosis, and health-related quality of life after stroke in a low-resource community in Chile (NANDU): (2021). a prospective population-based study. The Lancet Global Health.
  31. 31. Medeiros, G. C. (2020). et al. Post-stroke depression: A updated review. General Hospital Psychiatry.
  32. 32. Ladwig, S., & Werheid, K. (2020). Determinants of Antidepressant Treatment and Outpatient Rehabilitation Within the First Year After Stroke. Journal of Geriatric Psychiatry and Neurology, p. 0891988720973749.
  33. 33. Haslam, B. S. (2020). et al. Chronic pain following stroke: Current treatment and perceived effect. Disability and Health Journal, Vol. 14, 1.
  34. 34. Li, X., & Morton, S. M. (2020). Effects of chronic antidepressant use on neurophysiological responses to tDCS post-stroke. Neuroscience letters, Vol. 717.
  35. 35. Li, X., & Zhang, C. (2020). Comparative efficacy of nine antidepressants in treating Chinese patients with post-stroke depression: A network meta-analysis. Journal of affective disorders, Vol. 266, 540.
  36. 36. Sivolap, Y. P., & Damulin, I. V. (2020). Stroke and Depression. Neuroscience and Behavioral Physiology, Vol. 50, 6.
  37. 37. Bangalore, S. (2020). et al. Economic burden associated with inadequate antidepressant medication management among patients with depression and known cardiovascular diseases: insights from a United States-based retrospective claims database analysis. Journal of medical economics, Vol. 23, 3.
  38. 38. Castilla-Guerra, L. (2020). et al. Pharmacological management of post-stroke depression. Expert review of neurotherapeutics, Vol. 20, 2.
  39. 39. Mikami, K. (2020). et al. Effective tools to predict depression in acute and subacute phase of ischemic stroke. The Journal of Neuropsychiatry and Clinical Neurosciences, p. appi. neuropsych. 20040076.
  40. 40. Gong, L. (2020). et al. The efficacy of integrative anti-depressive therapy on motor recovery after ischemic stroke-A randomized clinical trial. European Journal of Integrative Medicine, Vol. 35.
  41. 41. Prost, A. (2021). et al. Acute and long-term impairments regarding emotional symptoms and quality of life in patients suffering from transient ischemic attack and stroke. Neurological Research, p. 1.
  42. 42. Lin, C. (2020). et al. Depressive symptoms after stroke are associated with worse recovery. The International Journal of Psychiatry in Medicine, Vol. 55, 4.
  43. 43. Tang, W. K. (2020). et al. Depression after subarachnoid hemorrhage: a systematic review. Journal of stroke, Vol. 22, 1.
  44. 44. Teasell, R. (2020). et al. Canadian stroke best practice recommendations: rehabilitation, recovery, and community participation following stroke. Part one: rehabilitation and recovery following stroke Update 2019. International Journal of Stroke, Vol. 15, 7.
  45. 45. Lanctot, K. L. (2020). et al. Canadian stroke best practice recommendations: mood, cognition and fatigue following stroke, update 2019. International Journal of Stroke, Vol. 15, 6.
  46. 46. Brzezinska, A. (2020). et al. Depression in dementia or dementia in depression? Systematic review of studies and hypotheses. Current Alzheimer Research, Vol. 17, 1.
  47. 47. Wu, J. J. (2020). et al. Late-life depression and the risk of dementia in 14 countries: a 10-year follow-up study from the Survey of Health, Ageing and Retirement in Europe. Journal of affective disorders, Vol. 274.
  48. 48. Brown, E. E., Rajji, T. K., & Mulsant, B. H. (2020). Why Do Some Older Adults Treated with Antidepressants Progress to Dementia?. The Journal of Clinical Psychiatry, Vol. 81, 5.
  49. 49. Santabarbara, J., Villagrasa, B., & Gracia-Garcia, P. (2020). Does depression increase the risk of dementia? Updated meta-analysis of prospective studies. Actas Esp Psiquiatr, Vol. 48, 4.
  50. 50. Power, M. C. (2020). et al. Little progress in reducing relative racial disparities in the incidence and prevalence of dementia in the United States, 2000-2016: Epidemiology: Dementia and risk in underrepresented populations. Alzheimer's & Dementia, Vol. 16.
  51. 51. Cao, Q. (2020). et al. The prevalence of dementia: a systematic review and metaanalysis. Journal of Alzheimer's Disease, Vol. 73, 3.
  52. 52. Diniz, B. S. (2020). et al. Mood Disorders and Dementia: Time for Action. The American Journal of Geriatric Psychiatry, Vol. 28, 5.
  53. 53. Dafsari, F. S., & Jessen, F. (2020). Depression-an underrecognized target for prevention of dementia in Alzheimer's disease. Translational Psychiatry, Vol. 10, 1.
  54. 54. Canton-Habas, V. (2020). et al. Depression as a Risk Factor for Dementia and Alzheimer's Disease. Biomedicines, Vol. 8, 11.
  55. 55. Banning, L. (2020). C P. et al. The association between biomarkers and neuropsychiatric symptoms across the Alzheimer's disease spectrum. The American Journal of Geriatric Psychiatry, Vol. 28, 7.
  56. 56. Ohoreorovwori, U. L. (2020). et al. Prevalence of and Severity of Depression among Parkinson Disease Patients. Journal of Advances in Medicine and Medical Research, p. 110.
  57. 57. Lee, Y. (2020). et al. Prevalence and associated factors of depressive disorder in caregivers of individuals with Parkinson disease. Journal of Geriatric Psychiatry and Neurology, p. 0891988720933359.
  58. 58. Wiels, W., Baeken, C., & Engelborghs, S. (2020). Depressive symptoms in the elderly-An early symptom of dementia? A systematic review. Frontiers in pharmacology, Vol. 11.
  59. 59. Jee, H. J. (2020). et al. Impact of sleep disorder as a risk factor for dementia in men and women. Biomolecules & therapeutics, Vol. 28, 1.
  60. 60. Mukku, S. S. (2020). R. et al. Depression and somatic symptoms in dementia: A narrative review. Journal of Geriatric Mental Health, Vol. 7, 1.
  61. 61. Lee, A. T. (2020). C. et al. Risk of Incident Dementia varies with Different Onset and Courses of Depression. Journal of Affective Disorders.
  62. 62. Ritchie, K. (2021). et al. Trauma and depressive symptomatology in middle-aged persons at high risk of dementia: the PREVENT Dementia Study. Journal of Neurology, Neurosurgery & Psychiatry, Vol. 92, 1.
  63. 63. Ritchie, K. (2021). et al. Trauma and depressive symptomatology in middle-aged persons at high risk of dementia: the PREVENT Dementia Study. Journal of Neurology, Neurosurgery & Psychiatry, Vol. 92, 1.
  64. 64. Brewster, K. (2020). et al. Age-related hearing loss, late-life depression, and risk for incident dementia in older adults. The American Journal of Geriatric Psychiatry, Vol. 28, 4.
  65. 65. Holmquist, S., Nordstrom, A., & Nordstrom, P. (2020). The association of depression with subsequent dementia diagnosis: A Swedish nationwide cohort study from 1964 to 2016. PLoS medicine, Vol. 17, 1.
  66. 66. Barczyk, Z. A., Douglas, K. M., & Porter, R. J. (2020). Baseline predictors of cognitive change in the treatment of major depressive episode: systematic review. BJPsych Open, Vol. 6.
  67. 67. Peakman, G. (2020). et al. Clinical factors associated with progression to dementia in people with late-life depression: A cohort study of patients in secondary care. BMJ open, Vol. 10, 5.
  68. 68. Dias, N. S. (2020). et al. Depressive disorders in the elderly and dementia: An update. Dementia & neuropsychologia, Vol. 14, 1.
  69. 69. Aajami, Z. (2020). et al. Relationship between depression and cognitive impairment among elderly: A cross-sectional study. Journal of Caring Sciences, Vol. 9, 3.
  70. 70. Carr, A. L. (2021). et al. Depression as a risk factor for dementia in older people with type 2 diabetes and the mediating effect of inflammation. Diabetologia, Vol. 64, 2.
  71. 71. Oh, D. J. (2020). et al. Chronic subsyndromal depression and risk of dementia in older adults. Australian & New Zealand Journal of Psychiatry, p. 0004867420972763.
  72. 72. Anstey, K. J. (2020). et al. Future Directions for Dementia Risk Reduction and Prevention Research: An International Research Network on Dementia Prevention Consensus. Journal of Alzheimer's Disease, . Preprint, 1.
  73. 73. Marcum, Z. A. (2020). et al. Engaging Patients to Design the Systematic Multi-Domain Alzheimer's Risk Reduction Trial (SMARRT) Intervention: Findings from a Web-Based Survey. Journal of Alzheimer's disease reports. Preprint. -p. 1-6.
  74. 74. Lin, C. E. (2020). et al Association between concurrent antidepressant and hypnotic treatment and the risk of dementia: A nationwide cohort study. Journal of Affective Disorders, Vol. 277, 549.
  75. 75. Bartels, C. (2020). et al. To be continued? long-term treatment effects of antidepressant drug classes and individual antidepressants on the risk of developing dementia: a German case-control study. The Journal of Clinical Psychiatry, Vol. 81, 5.
  76. 76. Alexopoulos, G. S. (2019). Mechanisms and treatment of late-life depression. Translational psychiatry, Vol. 9, 1.
  77. 77. Borda, M. G. et al. Benzodiazepines and antidepressants: effects on cognitive and functional decline in Alzheimer's disease and Lewy body dementia. (2020). -. International Journal of Geriatric Psychiatry.
  78. 78. Abdeljalil, A. B. (2020). et al. Antidepressant Use and Progression of Mild to Moderate Alzheimer's Disease: Results from the European ICTUS Cohort. Journal of the American Medical Directors Association.
  79. 79. Keir, L. H., & Breen, D. P. (2020). M., New awakenings: current understanding of sleep dysfunction and its treatment in Parkinson's disease. Journal of neurology, Vol. 267, 1.
  80. 80. Armstrong, M. J., & Okun, M. S. (2020). Diagnosis and treatment of Parkinson disease: a review. Jama, Vol. 323, 6.
  81. 81. Jones, S. (2020). et al. Neuropsychiatric symptoms in Parkinson's disease: aetiology, diagnosis and treatment. BJPsych Advances, Vol. 26, 6.
  82. 82. Jin, X. (2020). et al. The impact of mind-body exercises on motor function, depressive symptoms, and quality of life in Parkinson's disease: a systematic review and meta-analysis. International journal of environmental research and public health, Vol. 17, 1.
  83. 83. Zhao, N. (2020). et al. Quality of life in Parkinson's disease: A systematic review and meta-analysis of comparative studies. CNS Neuroscience & Therapeutics.
  84. 84. Chuquilin-Arista, F., Alvarez-Avellon, T., & Menendez-Gonzalez, M. (2020). Prevalence of depression and anxiety in Parkinson disease and impact on quality of life: a community-based study in Spain. Journal of geriatric psychiatry and neurology, Vol. 33, 4.
  85. 85. Mufti, S. (2020). LaFaver K. Mood Disorders in Parkinson's Disease. Psychiatric Annals, Vol. 50, 3.
  86. 86. Park, J. H. (2020). et al. Depressive symptoms are associated with worse cognitive prognosis in patients with newly diagnosed idiopathic Parkinson disease. Psychogeriatrics, Vol. 20, 6.
  87. 87. Kobylecki, C. (2020). Update on the diagnosis and management of Parkinson's disease. Clinical Medicine, Vol. 20, 4.
  88. 88. Contarino, M. F. (2020). et al. Effect of deep brain stimulation on caregivers of patients with Parkinson's disease: A systematic review. Parkinsonism & Related Disorders.
  89. 89. Ziesen, N. K., Kilian, H. M., & Schlaepfer, T. E. (2020). Beyond antidepressant effects of deep brain stimulation-A systematic qualitative approach. Personalized Medicine in Psychiatry, Vol. 23.
  90. 90. Vissani, M., Isaias, I. U., & Mazzoni, A. (2020). Deep brain stimulation: a review of the open neural engineering challenges. Journal of Neural Engineering, Vol. 17, 5.
  91. 91. Chang, Y. P. (2020). et al. Risk factors for depression in patients with Parkinson's disease: A nationwide nested case-control study. PloS one, Vol. 15, 7.
  92. 92. Gu, S. C. (2020). et al. Personalized prediction of depression in patients with newly diagnosed Parkinson's disease: A prospective cohort study. Journal of affective disorders, Vol. 268, 118.
  93. 93. (2020). Scherbaum R et al. Parkinson's Disease Multimodal Complex Treatment improves motor symptoms, depression and quality of life. Journal of neurology, Vol. 267, 4.
  94. 94. Assogna, F. (2020). et al. Drug Choices and Advancements for Managing Depression in Parkinson's Disease. Current neuropharmacology, Vol. 18, 4.
  95. 95. Fabbri, M. (2020). et al. Challenges and Perspectives in the Management of Late-Stage Parkinson's Disease. Journal of Parkinson's Disease, . Preprint, 1.
  96. 96. Stuhec, M., & Stoppe, G. (2020). Psychopharmacotherapy in Aged Patients. NeuroPsychopharmacotherapy, p. 1.
  97. 97. Iwaki, H. (2020). et al. A double-blind, randomized controlled trial of duloxetine for pain in Parkinson's disease. Journal of the neurological sciences, Vol. 414.
  98. 98. Nastitie, F., Abdulllah, S., & Nurrohmah, S. (2021). Analysis of factors associated with early-stage Parkinson's disease based on daily activities and sleeping behaviour disorder. Journal of Physics: Conference Series, 1722. IOP Publishing.
  99. 99. Konyushok, M. (2020). Why Neurologists Should Remember About Antidepressants. bipolar disorder, Vol. 2.
  100. 100. Karnik, V. (2020). et al. Current Status of Pain Management in Parkinson's Disease. Canadian Journal of Neurological Sciences, Vol. 47, 3.
  101. 101. Rodrigues-Amorim, D. (2020). et al. A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine. Frontiers in psychiatry, Vol. 11.
  102. 102. Buhmann, C., Kassubek, J., & Jost, W. H. (2020). Management of Pain in Parkinson's Disease. Journal of Parkinson's Disease, . Preprint, 1.
  103. 103. Aris, A. (2021). et al. Clinical Trials on Management of Pain in Parkinson's Disease. Clinical Trials in Parkinson's Disease, Humana, New York,. NY.
  104. 104. Tai, Y. C., & Lin, C. H. (2020). An overview of pain in Parkinson's disease. Clinical Parkinsonism & Related Disorders, Vol. 2, 1.
  105. 105. Nagamine, T. (2020). Duloxetine, a serotonin and norepinephrine reuptake inhibitor, may be a double-edged sword for patients with advanced Parkinson's disease. Asian journal of psychiatry, Vol. 50.
  106. 106. Greten, S. (2020). et al. Drug safety profiles in geriatric patients with Parkinson's disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis. Journal of Neural Transmission, p. 1.
  107. 107. Javidnia, M. (2020). et al. Pharmacotherapy Use for Non-Motor Symptoms Among de novo Parkinson's Disease Parkinson's Progression Markers Initiative Participants. Journal of Parkinson's disease, . Preprint, 1.
  108. 108. Miliukhina, I. V. (2020). Primenenie Vortioksetina pri depressii u patsientov s bolezn'iu Parkinsona na rannikh i razvernutykh stadiiakh zabolevaniia. Nevrologiia, neiropsikhiatriia, psikhosomatika, T. 12, 5, 40-45.
  109. 109. Barbato, G. et al. Vortioxetine for the treatment of depressive episodes associated with Parkinson's disease: a case series of six patients. Cited in: EMBASE-Excerpta Medica Database* Index Copernicus* PsycINFO* SCOPUS* Google Scholar* Emerging Sources Citation Index (ESCI), a new edition of Web of Science. -p. 248.
  110. 110. Behlke, L. M., Lenze, E. J., & Carney, R. M. (2020). The cardiovascular effects of newer antidepressants in older adults and those with or at high risk for cardiovascular diseases. CNS drugs, p. 1.
  111. 111. Rutten, S. (2020). et al. Anxiety, depression and sleep disorders in Parkinson's disease: a complex interaction between body and mind. Tijdschrift voor psychiatrie, Vol. 62, 1.
  112. 112. Benedict, R. H. (2020). B. Cognition in multiple sclerosis: Charcot was right. The Lancet Neurology, Vol. 19, 10.
  113. 113. Knapik, A. (2020). et al. Affective Disorder and Functional Status as well as Selected Sociodemographic Characteristics in Patients with Multiple Sclerosis, Parkinson's Disease and History of Stroke. Medicina, Vol. 56, 3.
  114. 114. Blachut, M. et al. Prevalence of psychiatric disorders among patients with Multiple Sclerosis.
  115. 115. Knowles, L. M. (2020). et al. Depressive Symptoms and Suicidal Ideation in Progressive Multiple Sclerosis Compared with Relapsing-Remitting Multiple Sclerosis: Results from a Cross-sectional Survey. Archives of physical medicine and rehabilitation.
  116. 116. Romaniuc, A. (2020). et al. The Main Determinants for Suicidal Ideation in a Romanian Cohort of Multiple Sclerosis Patients. Behavioural neurology, Vol.
  117. 117. Silva-Moraes, M. H. (2020). et al. Suicidal behavior in individuals with Amyotrophic Lateral Sclerosis: a systematic review. Journal of Affective Disorders.
  118. 118. Hanna, M., & Strober, L. B. (2020). Anxiety and depression in Multiple Sclerosis (MS): Antecedents, consequences, and differential impact on well-being and quality of life. Multiple Sclerosis and Related Disorders, Vol. 44.
  119. 119. Kellerman, Q. D. (2020). et al. Risk factors for suicide in a national sample of veterans with multiple sclerosis. Archives of physical medicine and rehabilitation, Vol. 101, 7.
  120. 120. Tauil, C. B. (2021). et al. Depression and anxiety disorders in patients with multiple sclerosis: association with neurodegeneration and neurofilaments. Brazilian Journal of Medical and Biological Research, Vol. 54.
  121. 121. Podda, J. (2020). et al. Predictors of clinically significant anxiety in people with multiple sclerosis: A one-year follow-up study. Multiple Sclerosis and Related Disorders, Vol. 45.
  122. 122. Magyari, M., & Sorensen, P. S. (2020). Comorbidity in multiple sclerosis. Frontiers in Neurology, Vol. 11.
  123. 123. Masuccio, F. G. (2021). et al. Imaging and depression in multiple sclerosis: a historical perspective. Neurological Sciences, p. 1.
  124. 124. Kuchling, J., & Paul, F. (2020). Visualizing the central nervous system: imaging tools for multiple sclerosis and neuromyelitis optica spectrum disorders. Frontiers in Neurology, Vol. 11.
  125. 125. Hauer, L., Perneczky, J., & Sellner, J. (2020). A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications. Journal of Neurology, p. 1.
  126. 126. Lazzarotto, A. (2020). et al. Selective cerebellar atrophy associates with depression and fatigue in the early phases of relapse-onset multiple sclerosis. The Cerebellum, Vol. 19, 2.
  127. 127. Chisari, C. G. (2020). et al. An update on the pharmacological management of pain in patients with multiple sclerosis. Expert opinion on pharmacotherapy, Vol. 21, 18.
  128. 128. Patten, S. B. (2020). Current perspectives on co-morbid depression and multiple sclerosis. Expert Review of Neurotherapeutics, Vol. 20, 8.
  129. 129. Stefano, G. (2020). Di et al. Pharmacotherapeutic Options for Managing Pain in Multiple Sclerosis. CNS drugs, Vol. 34, 749.
  130. 130. Plantone, D. (2020). et al. A voxel-based lesion symptom mapping analysis of chronic pain in multiple sclerosis. Neurological Sciences, p. 1.
  131. 131. Solaro, C. (2013). et al. Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study. Clinical neuropharmacology, Vol. 36, 4.
  132. 132. Vollmer, T. L. (2014). et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Duloxetine for the Treatment of Pain in Patients with Multiple Sclerosis. Pain Practice, Vol. 14, 8.
  133. 133. Oliveira, R. A. (2020). A. et al. Pharmacological treatment of central neuropathic pain: consensus of the Brazilian Academy of Neurology. Arquivos de neuro-psiquiatria, Vol. 78, 11.
  134. 134. Hua, L. H. (2021). et al. Clinical characteristics of a large multi-center cohort of people with multiple sclerosis over age 60. Multiple sclerosis and related disorders, Vol. 47.
  135. 135. Sylla, M. (2020). et al. Prevalence, severity, and associations of depression in people with epilepsy in Guinea: A single-center study. Epilepsy & Behavior, Vol. 113.
  136. 136. Ajinkya, S., Fox, J., & Lekoubou, A. (2020). Trends in prevalence and treatment of depressive symptoms in adult patients with epilepsy in the United States. Epilepsy & Behavior, Vol. 105.
  137. 137. Barco, A. M., Martinez, M. R., & Restrepo, D. (2020). Z.,, Depression in people with epilepsy. What is the connection?. Revista Colombiana de Psiquiatria (English ed.), Vol. 49, 1.
  138. 138. Mesraoua, B. (2020). et al. Dramatic outcomes in epilepsy: depression, suicide, injuries, and mortality. Current medical research and opinion, Vol. 36, 9.
  139. 139. Theodore, W. H. (2021). Epilepsy in the Hippocratic collection: Seizures and syndromes. Epilepsy & Behavior, Vol. 115.
  140. 140. Kluger, B. M. (2020). et al. Would people living with epilepsy benefit from palliative care?. Epilepsy & Behavior, p. 107618.
  141. 141. Mameniskiene, R. (2020). et al. A Review of Accelerated Long-Term Forgetting in Epilepsy. Brain Sciences, Vol. 10, 12.
  142. 142. Eloge, J. C., Ross, D. A., & Cooper, J. J. (2020). Afflicted by the gods: the shared history and neurobiology of psychosis and epilepsy. Biological Psychiatry, Vol. 87, 12.
  143. 143. Yeung, A., & Rapoport, M. (2020). Paradoxical complete and spontaneous resolution of depression, psychosis, and suicidal ideation following a traumatic brain injury. Brain injury, Vol. 34, 10.
  144. 144. Gargiulo, A. J. (2021). M. et al. Epilepsy and Psychiatric Comorbidities: New Approaches and Perspectives. Psychiatry and Neuroscience Update, Springer,. Cham.
  145. 145. Patel, S. (2020). et al. Psychiatric and psychosocial morbidity 1 year after epilepsy surgery. Irish Journal of Psychological Medicine, p. 1.
  146. 146. Solli, E. (2020). et al. Deciphering the surgical treatment gap for drug-resistant epilepsy (DRE): A literature review. Epilepsia, Vol. 61, 7.
  147. 147. Mula, M. (2020). et al. Psychiatric comorbidities in people with epilepsy. Neurology: Clinical Practice.
  148. 148. Kanner, A. M. (2020). Psychiatric Comorbidities in Medication-Resistant Epilepsy. Medication-Resistant Epilepsy: Diagnosis and Treatment, p. 256.
  149. 149. Malgorzata, P. (2020). et al. Glutamatergic dysregulation in mood disorders: Opportunities for the discovery of novel drug targets. Expert Opinion on Therapeutic Targets, Vol. 24, 12.
  150. 150. Rhie, S. J., Jung, E. Y., & Shim, I. The role of neuroinflammation on pathogenesis of affective disorders. Journal of exercise rehabilitation. -2020-Vol. 16, . 1.
  151. 151. Marwein, S., Biswal, S., & Acharya, P. C. (2020). Hormones and Steroids as Neurotransmitters. Frontiers in Pharmacology of Neurotransmitters, Springer,. Singapore.
  152. 152. Basu, T., Maguire, J., & Salpekar, J. A. (2021). Hypothalamic-pituitary-adrenal axis targets for the treatment of epilepsy. Neuroscience Letters, p. 135618.
  153. 153. Barroca, N. C. (2021). B. et al. Evaluation of the HPA Axis' Response to Pharmacological Challenges in Experimental and Clinical Early-Life Stress-Associated Depression. Eneuro, Vol. 8.
  154. 154. Tolchin, B., & Hirsch, L. J. (2020). LaFrance W. C. Neuropsychiatric aspects of epilepsy. Psychiatric Clinics, Vol. 43, 2.
  155. 155. Scott, A. J. (2020). et al. Systematic review and meta-analysis of anxiety and depression in youth with epilepsy. Journal of pediatric psychology, Vol. 45, 2.
  156. 156. Ertan, D. (2021). et al. Anticipatory anxiety of epileptic seizures: An overlooked dimension linked to trauma history. Seizure, Vol. 85, 64.
  157. 157. Galicchio, S. (2021). et al. Self-limited epilepsy with centro-temporal spikes: A study of 46 patients with unusual clinical manifestations. Epilepsy Research, Vol. 169.
  158. 158. Melo, H. M. (2021). et al. Ictal fear is associated with anxiety symptoms and interictal dysphoric disorder in drug-resistant mesial temporal lobe epilepsy. Epilepsy & Behavior, Vol. 115.
  159. 159. Gugala-Iwaniuk, M. (2020). et al. The prevalence of depressive and anxiety symptoms in Polish epilepsy patients-The context of pharmaco-resistance. Epilepsy & Behavior, p. 107522.
  160. 160. Yin, F. (2021). et al. Auras in intractable frontal lobe epilepsy: Clinical characteristics, values, and limitations. Epilepsy & Behavior, Vol. 115.
  161. 161. Bargallo, N., & Blanco, E. C. (2020). How to interpret images in epileptic seizures: correlation between clinical and functional MRI findings. Radiologia (English Edition), Vol. 62, 2.
  162. 162. Andrews, J. P., & Chang, E. F. (2020). Temporal Neocortical Epilepsy. Stereotactic and Functional Neurosurgery: Principles and Applications, p. 367.
  163. 163. Thomas, R. H., & Osland, K. Learnings from deaths-the Epilepsy. (2020). Deaths Register. Epilepsy & Behavior, Vol. 103.
  164. 164. Thomas, R. H., Craig, D. P., & Leach, J. P. (2020). The view of the clinician and the scientist on the family experience of sudden epilepsy deaths. Epilepsy & Behavior, Vol. 103.
  165. 165. Pickrell, W. O., & Kerr, M. P. (2020). SUDEP and mortality in epilepsy: The role of routinely collected healthcare data, registries, and health inequalities. Epilepsy & Behavior, Vol. 103.
  166. 166. Harcourt, S. (2020). The neuropsychology of epilepsy and suicide: A review. Aggression and violent behavior, p. 101411.
  167. 167. Wirrell, E. C. (2020). et al. Self-injurious and suicidal behavior in young adults, teens, and children with epilepsy: A population-based study. Epilepsia, Vol. 61, 9.
  168. 168. Kim, S. J. (2020). et al. Clinical factors associated with suicide risk independent of depression in persons with epilepsy. Seizure, Vol. 80, 86.
  169. 169. Dagar, A. (2020). et al. Screening for suicidality and its relation to undiagnosed psychiatric comorbidities in children and youth with epilepsy. Epilepsy & Behavior, Vol. 113.
  170. 170. Shaikh, M. (2020). et al. The gut-brain-axis on the manifestation of depressive symptoms in epilepsy: an evidence-driven hypothesis. Frontiers in pharmacology, Vol. 11.
  171. 171. Clary, H. M. (2020). M. et al. Who is willing to participate in research? A screening model for an anxiety and depression trial in the epilepsy clinic. Epilepsy & Behavior, Vol. 104.
  172. 172. Stefanidou, M., Greenlaw, C., & Douglass, L. (2020). Mental health issues in transition-age adolescents and young adults with epilepsy. Seminars in Pediatric Neurology. WB Saunders.
  173. 173. Narapareddy, B. R. (2020). et al. Treatment of depression after traumatic brain injury: a systematic review focused on pharmacological and neuromodulatory interventions. Psychosomatics.
  174. 174. Teymoori, A. (2020). et al. Factorial structure and validity of Depression (PHQ-9) and Anxiety (GAD-7) scales after traumatic brain injury. Journal of clinical medicine, Vol. 9, 3.
  175. 175. Erler, K. S., Kew, C. L., & Juengst, S. B. (2020). Participation differences by age and depression 5 years after moderate-to-severe traumatic brain injury. International review of psychiatry, Vol. 32, 1.
  176. 176. Albrecht, J. S. (2020). et al. Treatment of depression after traumatic brain injury reduces risk of neuropsychiatric outcomes. Journal of neurotrauma, Vol. 37, 23.
  177. 177. Peppel, L. D., Ribbers, G. M., & Heijenbrok-Kal, M. H. (2020). Pharmacological and non-pharmacological interventions for depression after moderate-to severe traumatic brain injury: a systematic review and meta-analysis. Journal of neurotrauma, Vol. 37, 14.
  178. 178. Elliott, J. E. (2020). et al. Posttraumatic stress disorder increases the odds of REM sleep behavior disorder and other parasomnias in Veterans with and without comorbid traumatic brain injury. Sleep, Vol. 43, 3.
  179. 179. (2020). McIntyre A. et al. Anxiety, depression, and quality of life among subgroups of individuals with acquired brain injury: The role of anxiety sensitivity and experiential avoidance. Neurorehabilitation, . Preprint. p. 1.
  180. 180. Marinkovic, I. (2020). et al. Prognosis after mild traumatic brain injury: influence of psychiatric disorders. Brain sciences, Vol. 10, 12.
  181. 181. Hicks, A. J. (2020). et al. Efficacy and Harms of Pharmacological Interventions for Anxiety after Traumatic Brain Injury: Systematic Review. Journal of Neurotrauma.
  182. 182. Fakhoury, M. (2020). et al. Depression following traumatic brain injury: a comprehensive overview. Reviews in the Neurosciences, Vol. 1, .
  183. 183. Albayram, O., Albayram, S., & Mannix, R. (2020). Chronic traumatic encephalopathy-a blueprint for the bridge between neurological and psychiatric disorders. Translational Psychiatry, Vol. 10, 1.
  184. 184. Zhou, Y. (2020). et al. Dual roles of astrocytes in plasticity and reconstruction after traumatic brain injury. Cell Communication and Signaling, Vol. 18, 1.
  185. 185. Mukherjee, S. (2020). et al. Neuroinflammatory mechanisms of post-traumatic epilepsy. Journal of neuroinflammation, Vol. 17, 1.
  186. 186. Jolly, A. E. (2020). et al. Detecting axonal injury in individual patients after traumatic brain injury. Brain.
  187. 187. Graham, N. S. (2020). N. et al. Diffuse axonal injury predicts neurodegeneration after moderate-severe traumatic brain injury. Brain, Vol. 143, 12.
  188. 188. Cardim, D. (2020). et al. Effects of age and sex on optic nerve sheath diameter in healthy volunteers and patients with traumatic brain injury. Frontiers in Neurology, Vol. 11.
  189. 189. Cusimano, M. D. (2020). et al. A population-based study of fall-related traumatic brain injury identified in older adults in hospital emergency departments. Neurosurgical focus, Vol. 49, 4.
  190. 190. Gils, A. (2020). van et al. Management of mild traumatic brain injury. Practical neurology, Vol. 20, 3.
  191. 191. Bogner, J. (2020). et al. Lifetime history of traumatic brain injury and behavioral health problems in a population-based sample. The Journal of head trauma rehabilitation, Vol. 35, 1.
  192. 192. Krishna, G. (2020). et al. Approaches to monitor circuit disruption after traumatic brain injury: frontiers in preclinical research. International journal of molecular sciences, Vol. 21, 2.
  193. 193. (2021). McIntire K. S. et al. Factors increasing the risk of suicide after traumatic brain injury: a state-of-the-science review of military and civilian studies. Brain injury, p. 1.
  194. 194. Serafini, R. A., Pryce, K. D., & Zachariou, V. (2020). The mesolimbic dopamine system in chronic pain and associated affective comorbidities. Biological psychiatry, Vol. 87, 1.
  195. 195. Wager, J. (2020). et al. Prevalence and associated psychosocial and health factors of chronic pain in adolescents: Differences by sex and age. European Journal of Pain, Vol. 24, 4.
  196. 196. Cherif, F. (2020). et al. Depression prevalence in neuropathic pain and its impact on the quality of life. Pain Research and Management, Vol..
  197. 197. Harrisson, S. A. (2020). et al. Prevalence, Characteristics, and Clinical Course of Neuropathic Pain in Primary Care Patients Consulting with Low Backrelated Leg Pain. The Clinical Journal of Pain, Vol. 36, 11.
  198. 198. Koster-Brouwer, M. E. (2020). et al. Occurrence and risk factors of chronic pain after critical illness. Critical care medicine, Vol. 48, 5.
  199. 199. Freynhagen, R., Rey, R., & Argoff, C. (2020). When to consider "mixed pain"? The right questions can make a difference!. Current Medical Research and Opinion, Vol. 36, 12.
  200. 200. Liampas, A. (2020). et al. Prevalence and management challenges in central post-stroke neuropathic pain: A systematic review and meta-analysis. Advances in therapy, Vol. 37, 3278.
  201. 201. Gruener, H. (2020). et al. Biomarkers for predicting central neuropathic pain occurrence and severity after spinal cord injury: results of a long-term longitudinal study. Pain, Vol. 161, 3.
  202. 202. Yilmazer, C. et al. Clinical perspective on pain in multiple sclerosis. Multiple Sclerosis Journal. SAGE Publications-2020, p. 135245852095201. doi:10.1177/1352458520952015.
  203. 203. Viswanath, O. (2020). et al. Central neuropathic mechanisms in pain signaling pathways: current evidence and recommendations. Advances in therapy, Vol. 37, 5.
  204. 204. Moisset, X. (2020). et al. Pharmacological and non-pharmacological treatments for neuropathic pain: systematic review and French recommendations. Revue Neurologie, Vol. 176, 5.
  205. 205. Selvy, M. (2020). et al. The safety of medications used to treat peripheral neuropathic pain, part 1 (antidepressants and antiepileptics): review of double blind, placebo-controlled, randomized clinical trials. Expert opinion on drug safety, Vol. 19, 6.
  206. 206. Hall, O. M. (2020). et al. Novel Agents in Neuropathic Pain, the Role of Capsaicin: Pharmacology, Efficacy, Side Effects, Different Preparations. Current Pain and Headache Reports, Vol. 24, 9

Comments(0)

When adding a comment stipulate:
  • the relevance of the published material;
  • general estimation (originality and relevance of the topic, completeness, depth, comprehensiveness of topic disclosure, consistency, coherence, evidence, structural ordering, nature and the accuracy of the examples, illustrative material, the credibility of the conclusions;
  • disadvantages, shortcomings;
  • questions and wishes to author.